Cardiovascular Diseases

Nevro Received FDA Approval of its 10 kHz High-Frequency Spinal Cord Stimulation Therapy for Treatment of Chronic Pain Associated with Painful Diabetic Neuropathy On July 19, 2021, Nevro Corp. received approval for its Senza System, Nevro's unique 10 kHz stimulation, to treat chronic pain associated with Painful Diabetic Neuropathy (PDN). The company plans to initiate commercial launch activities in the US under its recently launched HFX™ branding, as HFX™ for PDN. The Chairman, Chief Executive Officer and President of Nevro, D. Keith Grossman,  "This FDA approval marks a capstone achievement that demonstrates the strength of our clinical data...